FrancophonIA/ELRC3.0 huggingface dataset:
English: - Drowsiness, decreased level of consciousness, confusion, hallucination.
Maltese: - Ngħas, livell imnaqqas ta' koxjenza, konfużjoni, alluċinazzjoni
English: Uncommon Amenorrhoea, Hyperprolactinaemia, Rare
Maltese: Amenorea, Iperprolatinemija.
English: In patients with moderate to severe renal impairment (Creatinine clearance 15-60 ml/min), the dose should be reduced by 50% (see section 5.2).
Maltese: F'pazjenti b'indeboliment moderat sa sever tal-kliewi (Tneħħija ta' kreatinina 15-60 ml/min), id-doża għandha titnaqqas b'50% (ara sezzjoni 5.2)
English: These may be signs of an allergic reaction, which may be severe.
Maltese: Dawn jistgħu jkunu sinjali ta' reazzjoni allerġika, li tista' tkun severa
English: Metoclopramide exposure levels are increased when co-administered with strong CYP2D6 inhibitors such as fluoxetine and paroxetine.
Maltese: Livelli ta' esponiment ta' metoclopramide jogħlew meta jingħata flimkien ma' impedituri qawwija ta' CYP2D6 bħal fluoxetine u paroxetine.
English: Contraindicated combination Levodopa or dopaminergic agonists and metoclopramide have a mutual antagonism (see section 4.3).
Maltese: Levodopa jew agonisti dopaminerġiċi u metoclopramide għandhom antaġoniżmu reċiproku (ara sezzjoni 4.3).
English: Metoclopramide-containing products
Maltese: Prodotti li fihom metoclopramide
English: Treatment must be discontinued if clinical signs of tardive dyskinesia appear.
Maltese: It-trattament għandu jitwaqqaf jekk jidhru sinjali kliniċi ta' diskinesja tardiva.
English: In cases of abnormal levels (methaemoglobinemia), the treatment should be immediately and permanently stopped.
Maltese: F'każijiet ta' livelli abnormali (metaemoglobinemija), il-kura għandha titwaqqaf minnufih u b'mod permanenti.
English: Extrapyramidal disorders, drowsiness, decreased level of consciousness, confusion, hallucination, and cardio-respiratory arrest may occur.
Maltese: Disturbi ekstrapiramidali, ħedla, livell imnaqqas ta' koxjenza, konfużjoni, alluċinazzjoni, u arrest kardjorespiratorju jistgħu jseħħu.
English: Not known Tardive dyskinesia which may be persistent, during or after prolonged treatment, particularly in elderly patients (see section 4.4), Neuroleptic malignant syndrome (see section 4.4)
Maltese: Diskinesja tardiva li tista' tkun persistenti waqt jew wara trattament fit-tul, b'mod partikolari f'pazjenti anzjani (ara sezzjoni 4.4), Sindromu newrolettiku malinn (ara sezzjoni 4.4)
English: In patients with end stage renal disease (Creatinine clearance ≤ 15 ml/min), the daily dose should be reduced by 75%.
Maltese: F'pazjenti b'mard tal-kliewi tal-aħħar stadju (Tneħħija ta' kreatinina ≤ 15 ml/min), id-doża ta' kuljum għandha titnaqqas bi 75%.
English: These movements will stop when when treated appropriately.
Maltese: Arrest tas-sinus partikolarment bil-formolazzjoni li tingħata ġol-vina.
English: A symptomatic treatment and a continuous monitoring of the cardiovascular and respiratory functions should be carried out according to clinical status.
Maltese: Trattament sintomatiku u monitoraġġ kontinwu tal-funzjonijiet kardkovaskulari u respiratorji għandhom jitwettqu skont l-istat kliniku.
English: Prolonged treatment with metoclopramide may cause tardive dyskinesia, potentially irreversible, especially in the elderly.
Maltese: Trattament ipprolongat b'metoclopramide jista' jikkaġuna diskinesja tardiva, li hija potenzjalment irriversibbli, speċjalment fl-anzjani.
English: Metoclopramide injection may prolong the duration of neuromuscular block (through inhibition of plasma cholinesterase).
Maltese: Injezzjoni ta' metoclopramide tista' ttawwal l-imblokk newromuskolari (permezz ta' impediment ta' cholinesterase fil-plażma).
English: For prolonged release preparations 15mg strength
Maltese: Għal preparazzjonijiet ta' rilaxx prolongat qawwa ta' 15mg
English: Metoclopramide should be discontinued immediately in the event of extrapyramidal symptoms.
Maltese: Metoclopramide għandu jitwaqqaf minnufih f'każ ta' sintomi ekstrapiramidali.
English: For all formulations - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 - Gastrointestinal haemorrhage, mechanical obstruction or gastro-intestinal perforation for which the stimulation of gastrointestinal motility constitutes a risk - Confirmed or suspected pheochromocytoma, due to the risk of severe hypertension episodes - History of neuroleptic or metoclopramide-induced tardive dyskinesia - Epilepsy (increased crises frequency and intensity) - Parkinson's disease - Combination with levodopa or dopaminergic agonists (see section 4.5) - Known history of methaemoglobinaemia with metoclopramide or of NADH cytochrome-b5
Maltese: Għal kull formulazzjoni jekk inti allerġiku għal metoclopramide jew għal xi sustanza oħra ta' din il-mediċina (elenkati f'sezzjoni 6). għandek emorraġija, sadd jew tiċrita fl-istonku jew f'imsarnek. għandek jew jista' jkollok tumur rari tal-glandola adrenali, li joqgħod qrib il-kliewi (feokromoċitoma). qatt kellek spażmi muskolari involontarji (diskinesja tardiva), meta tkun ġejt ikkurat b'mediċina. ikollok l-epilessija ikollok il-mard ta' Parkinson qed tieħu levodopa (mediċina għall-marda ta' Parkinson) jew agonisti dopaminerġiċi (ara taħt "Mediċini oħra u Tradename")
English: Endocrine disorders*
Maltese: Disturbi fis-sistema endokrinarja* Mhux komuni
English: In case of extrapyramidal symptoms related or not to overdose, the treatment is only symptomatic (benzodiazepines in children and/or anticholinergic anti-parkinsonian medicinal products in adults).
Maltese: F'każ ta' sintomi ekstrapiramidali relatati jew le ma' doża eċċessiva, it-trattament hu biss sintomatiku (benzodiazepines fi tfal u/jew prodotti mediċinali antikolinerġiċi ta' kontra l-parkinson f'adulti).
English: The medicine will normally be given to you by a doctor or a nurse.
Maltese: Il-mediċina ġeneralment ser tingħatalek minn tabib jew infermier.
English: In patients with cirrhosis of the liver, accumulation of metoclopramide has been observed, associated with a 50% reduction in plasma clearance.
Maltese: F'pazjenti b'ċirrosi tal-fwied, akkumulazzjoni ta metoclopramide ġiet osservata, assoċjata ma' tnaqqis ta' 50% fit-tneħħija mill-plażma.
English: The use of metoclopramide with serotonergic drugs such as SSRIs may increase the risk of serotonin syndrome.
Maltese: L-użu ta' metoclopramide ma' mediċini sertonerġiċi bħal SSRIs jista' jżid ir-riskju ta' sindromu ta' serotonin.
English: These may be signs of a condition called neuroleptic malignant syndrome.
Maltese: Dawn jistgħu jkunu sinjali ta' kondizzjoni msejħa sindromu newrolettiku malinn.
English: Prevention of delayed chemotherapy induced nausea and vomiting (CINV) (paediatric patients aged 118 years)
Maltese: Prevenzjoni ta' tqalligħ u remettar tardiv indotti mill-kimoterapija (CINV) (pazjenti pedjatriċi ta' bejn 1 - 18-il sena)
English: Adult population {Tradename} is indicated in adults for: - Prevention of post operative nausea and vomiting (PONV) - Symptomatic treatment of nausea and vomiting, including acute migraine induced nausea and vomiting - Prevention of radiotherapy induced nausea and vomiting (RINV).
Maltese: Popolazzjoni adulta {Tradename} huwa indikat f'adulti għal: - Prevenzjoni ta' tqalligħ u remettar ta' wara l-operazzjoni (PONV - post-operative nausea and vomiting) - Trattament sintomatiku għal tqalligħ u remettar, li jinkludi tqalligħ u remettar indotti minn emigranja akuta.
English: The maximum treatment duration is 5 days for prevention of delayed chemotherapy induced nausea and vomiting (CINV).
Maltese: It-tul massimu ta' trattament hu ta' 5 ijiem għal prevenzjoni ta' tqalligħ u remettar tardiv indotti mill-kimoterapija (CINV)
English: Symptoms of Parkinson's disease may also be exacerbated by metoclopramide.
Maltese: Sintomi tal-marda ta' Parkinson jistgħu wkoll jiħraxu b'metoclopramide.
English: Adult population {Tradename} is indicated in adults for: - Prevention of delayed chemotherapy induced nausea and vomiting (CINV) - Prevention of radiotherapy induced nausea and vomiting (RINV) 4.2 Posology and method of administration
Maltese: Popolazzjoni adulta {Tradename} huwa indikat f'adulti għal: - Prevenzjoni ta' tqalligħ u remettar tardiv indotti minħabba kimoterapija (CINV) - Prevenzjoni ta' tqalligħ u remettar indotti minħabba radjoterapija (RINV) 4.2 Pożoloġija u metodu ta' kif għandu jingħata Rotta parenterali
English: Blood and lymphatic system disorders Not known Methaemoglobinaemia, which could be related to NADH cytochrome b5 reductase deficiency, particularly in neonates (see section 4.4)
Maltese: Metaemoglobinemija, li tista' tiġi marbuta ma nuqqas ta' NADH cytochrome b-5 reductase, b'mod partikolari fi trabi li għadhom kif twieldu (ara sezzjoni 4.4)
English: For prevention of PONV a single dose of 10mg is recommended.
Maltese: Għal prevenzjoni ta' PONV doża waħda ta' 10 mg hija rakkomandata
English: Common (may affect up to 1 in 10 people) depression uncontrollable movements such as tics, shaking, twisting movements or muscle contracture (stiffness, rigidity) symptoms similar to Parkinson disease (rigidity, tremor) feel restless blood pressure decrease (particularly with intravenous route) diarrhoea feeling weak.
Maltese: Komuni (tista' taffettwa sa persuna 1 f'10) dipressjoni movimenti inkontrollabbli bħal ġbid, tixxengel, tkawwiġ jew kontrazzjonijiet muskolari (ebusija, riġidità) sintomi simili għal Parkinson (riġidità, rogħda) tħossok m'għandekx kwiet tnaqqis fil-pressjoni tad-demm (partikolarment meta jittieħed minn ġol-vina) dijarea tħpossok dgħajjef
English: Sinus arrest particularly with intravenous formulation; Electrocardiogram QT prolonged; Torsade de Pointes;
Maltese: Titwil tal-elettrokardjogramma ta' QT. Torsade de Pointes;
English: Careful monitoring of cyclosporine plasma concentration is required.
Maltese: Monitoraġġ attent tal-konċentrazzjoni ta' cyclosporine fil-plażma huwa meħtieġ.
English: The recommended dose is 0.1 to 0.15 mg/kg body weight, repeated up to 3 times daily, taken by mouth (oral route).
Maltese: Id-doża rakkomandata hi ta' 0.1 sa 0.15 mg/kg piż tal-ġisem, ripetuta għal sa 3 darbiet kuljum billi tingħata mill-ħalq.(rotta orali).
English: Metoclopramide may decrease digoxin bioavailability.
Maltese: Metclopramide jista' jnaqqas il-bijodisponibilità ta' digoxin.
English: Convulsion especially in epileptic patients
Maltese: Konvulsjoni speċjalment f'pazjenti epilettiċi
English: Intravenous doses should be administered as a slow bolus (at least over 3 minutes) in order to reduce the risk of adverse effects (e.g. hypotension, akathisia).
Maltese: Dożi intravenużi għandhom jiġu amministrati b'bolus bil-mod (tal-anqas fuq 3 minuti) sabiex jitnaqqas ir-riskju ta' effetti avversi (eż pressjoni għolja, akatisja)
English: Somnolence
Maltese: Galatorea
English: Elderly
Maltese: Astenija
English: The maximum recommended daily dose is 30 mg or 0.5mg/kg body weight.
Maltese: Id-doża massima rakkomandata ta' kuljum hi ta' 30 mg jew 0.5 mg/kg ta' piż tal-ġisem.
English: For the treatment of nausea and vomiting including nausea and vomiting which may occur with a migraine and for the prevention of nausea and vomiting caused by radiotherapy: the recommended single dose is 10 mg, repeated up to 3 times daily.
Maltese: Għat-trattament ta' tqalligħ u remettar, li jinkludi taqlligħ u remettar li jista' jseħħ ma' emigranja u għall-prevenzjoni ta' tqalligħ u remettar ikkaġunati minn radjoterapija, id-doża unika rakkomandata hija ta 10 mg, li tiġi ripetuta sa 3 darbiet kuljum.
English: Paediatric population {Tradename} is indicated in children (aged 1-18 years) for: - Prevention of delayed chemotherapy induced nausea and vomiting (CINV) as a second line option Rectal route
Maltese: Popolazzjoni pedjatrika {Tradename} hu indikat fi tfal (ta' età bejn 1-18-il sena) għal: - Prevenzjoni ta' tqalligħ u remettar tardiv indotti minħabba kimoterapija (CINV- chemotherapy induced nausea and vomiting) bħala t-tieni linja ppreferuta ta' kura Meta jingħata mir-rektum
English: {Tradename} if”) - anticholinergics (medicines used to relieve stomach cramps or spasms) - morphine derivatives (medicines used to treat severe pain) - sedative medicines - any medicines used to treat mental health problems - digoxin (medicine used to treat heart failure) - cyclosporine (medicine used to treat certain problems with the immune system) - mivacurium and suxamethonium (medicines used to relax muscles)
Maltese: Dawn il-mediċini jinkludu dawn li ġejjin: levodopa jew mediċini oħra li jintużaw biex jittrattaw il-marda ta' parkinson (ara hawn fuq "Tiħux Tradename jekk") antikolinerġiċi (mediċini użati biex itaffu bugħawwiġijiet jew spasmi fl-istonku) derivati tal-morfina (mediċini użati biex itaffu uġigħ sever) mediċini sedattivi kull mediċina użata biex tittratta problemi ta' saħħa mentali digoxin (mediċina użata biex tittratta falliment tal-qalb) cyclosporine (mediċina użata biex tittratta ċertu problemi mas-sistema immuni) mivacurium u suxamethonium (mediċini użati biex jirilassaw il-muskoli) fluoxetine u paroxetine (mediċina użata għad-dipressjoni)
English: There have been reports of serious cardiovascular undesirable effects including cases of circulatory collapse, severe bradycardia, cardiac arrest and QT prolongation following administration of metoclopramide by injection, particularly via the intravenous route (see section 4.8).
Maltese: Kien hemm rapporti ta' effetti kardjovaskulari serji mhux mixtieqa li jinkludu każijiet ta' kollass ċirkolatorju, bradikardja severa, arrest kardijaku u titwil ta' QT wara l-għoti ta' metoclopramide b'injezzjoni, partikolarment meta ngħata ġo vina (ara sezzjoni 4.8)
English: Pregnancy
Maltese: Dipressjoni
English: For the 30 mg strengh prolonged release preparations
Maltese: Għall-preparazzjonijiet ta' rilaxx ipprolongat ta' 30 mg
English: A minimal interval of 24 hours between two administrations is to be respected, even in case of vomiting or rejection of the dose (see section 4.4).
Maltese: Intervall minimu ta' 24 siegħa bejn żewġ amministrazzjonijiet għandu jiġi rispettat, anke f'każ ta' remettar jew riġettar tad-doża (ara sezzjoni 4.4).
English: For formulations which cannot be used to administer a 5mg dose Tablets/capsules/granules are not suitable for use in children weighing less than 61 kg. Other pharmaceutical forms/strengths may be more appropriate for administration to this population.
Maltese: Għal formulazzjonijiet li ma jistgħux jintużaw biex tiġi amministrata doża ta' 5 mg Pilloli/kapsuli/granijiet mhumiex adttati għal użu fi tfal li jiżnu inqas minn 61 kg Għamliet/qawwiet farmaċewtiċi oħra jistgħu jkunu aktar adattati għall-għoti lil din il-popolazzjoni.
English: Common Extrapyramidal disorders (particularly in children and young adults and/or when the recommended dose is exceeded, even following administration of a single dose of the drug) (see section 4.4), Parkinsonism, Akathisia
Maltese: Disturbi ekstrapiramidali (b'mod partikolari fi tfal u adulti żgħar u/jew meta d-doża rakkomandata hija maqbuża, anke wara l-għoti ta' doża waħda tal-mediċina) (ara sezzjoni 4.4) Parkinsoniżmu, Akatisja
English: Renal impairment
Maltese: Disturb vaskulari
English: The recommended dose is 0.1 to 0.15 mg/kg body weight, repeated up to 3 times daily, given by slow injection into a vein.
Maltese: Id-doża rakkomandata hi ta' 0.1 sa 0.15 mg/kg piż tal-ġisem, ripetuta sa 3 darbiet kuljum, mogħtija b'injezzjoni bil-mod ġo vina.
English: Anticholinergics and morphine derivatives may have both a mutual antagonism with metoclopramide on the digestive tract motility.
Maltese: L-antikolinerġiċi u derivati tal-morfina jista' t-tnejn ikollhom antagoniżmu reċiproku b'metoclopramide fuq iċ-ċaqlieq fil-passaġġ diġestiv.
English: Combination to be taken into account Due to the prokinetic effect of metoclopramide, the absorption of certain drugs may be modified.
Maltese: Il-kombinazzjoni għandha tittieħed inkonsiderazzjoni Minħabba l-effett prokinetiku ta' metoclopramide, l-assorbiment ta' ċertu mediċini jista' jiġi modifikat.
English: The recommended single dose is 15 mg, repeated up to twice daily.
Maltese: Id-doża unika rakkomandata hi ta' 15 mg, ripetuta sa tliet darbiet kuljum qawwa ta' 30 mg
English: For the symptomatic treatment of nausea and vomiting, including acute migraine induced nausea and vomiting and for the prevention of radiotherapy induced nausea and vomiting (RINV): the recommended single dose is 10 mg, repeated up to three times daily
Maltese: Għat-trattament simtomatiku ta' tqalligħ u remettar, li jinkludi taqlligħ u remettar indotti minn emigranja u għal tqalligħ u remettar indotti minn radjoterapija (RINV), id-doża unika rakkomandata hija ta 10 mg li tiġi ripetuta sa tliet darbiet kuljum.
English: Not known (frequency cannot be estimated from the available data) abnormal blood pigment levels: which may change the colour of your skin abnormal development of breasts (gynaecomastia) involuntary muscle spasms after prolonged use, particularly in elderly patients high fever, high blood pressure, convulsions, sweating, production of saliva.
Maltese: Mhux magħruf (il-frekwenza ma tistax tiġi stmata mit-tagħrif disponibbli) livelli abnormali ta' pigment fid-demm, li jistgħu jibdlu l-kulur tal-ġilda tiegħek żvilupp abnormali tal-isdieri (ginekomastja) spażmi involontarji tal-muskoli wara użu fit-tul, b'mod partikolari f'pazjenti anzjani. deni għoli, pressjoni għolja, konvulsjonijiet, għaraq, produzzjoni ta riq.
English: In such cases, metoclopramide should be immediately and permanently discontinued and appropriate measures initiated (such as treatment with methylene blue).
Maltese: F'każijiet bħal dawn, metoclopramide għandu jitwaqqaf immedjatament u b'mod permanenti u mużuri xierqa mibdija (bħal tratatment b'methylene blue).
English: Special care should be exercised in patients with underlying neurological conditions and in patients being treated with other centrally-acting drugs (see section 4.3)
Maltese: Attenzjoni speċjali għandha tingħata lil pazjenti b'kondizzjonijiet newroloġiċi fl-isfond u f'pazjenti li qed jiġu kkurati b'mediċini oħra li jaġixxu b'mod ċentrali (ara sezzjoni 4.3)
English: For formulations which can be used to administer a 5mg dose Tablets/capsules/granules are not suitable for use in children weighing less than 30 kg. Other pharmaceutical forms/strengths may be more appropriate for administration to this population
Maltese: Għal formulazzjonijiet li jistgħu jintużaw biex tiġi amministrata doża ta' 5 mg Pilloli/kapsuli/granijiet mhumiex adttati għal użu fi tfal li jiżnu inqas minn 30 kg Għamliet/qawwiet farmaċewtiċi oħra jistgħu jkunu aktar adattati għall-għoti lil din il-popolazzjoni.
English: For the prevention of nausea and vomiting that may occur after surgery prevention: a single dose of 10mg is recommended.
Maltese: Għall-prevenzjoni ta' tqalligħ u remettar li jistgħu jseħħu wara operazzjoni, doża waħda ta' prevenzjoni ta' 10 mg hija rakkomandata.
English: Additional statements related to excipients
Maltese: Dikjarazzjonijiet addizzjonali marbuta ma' eċċipjenti
English: Metoclopramide is excreted in breast milk at low level.
Maltese: Metoclopramide jista' jintuża fit-tqala jekk meħtieġ b'mod kliniku.
English: Uncommon Dystonia, Dyskinesia, Depressed level of consciousness
Maltese: Distonja, Diskinesja, Livell imnaqqas ta' koxjenza
English: Dosing table
Maltese: Ħedla
English: Pregnancy, breast-feeding For all routes of administration
Maltese: Tagħmir/struzzjonijiet għall-użu
English: Galactorrhoea Not known Gynaecomastia
Maltese: Disturbi fis-sistema immuni Mhux komuni
English: Uncommon (may affect up to 1 in 100 people) raised levels of a hormone called prolactin in the blood which may cause: milk production in men, and women who are not breast-feeding irregular periods hallucination decreased level of consciousness slow heartbeat (particularly with intravenous route) allergy
Maltese: Mhux komuni (tista' taffettwa sa persuna 1 f'100) livelli ogħla ta' ormon li jissejjaħ prolactin fid-demm li jista' jikkaġuna produzzjoni tal-ħalib f'irġiel, u f'nisa li ma jkunux qed ireddgħu. pirjids irregolari alluċinazzjoni livell imnaqqas ta' koxjenza qalb tħabbat bil-mod (partikolarment meta jingħata minn ġol-vina) allerġija
English: Older people The dose may need to be reduced depending on kidney problems, liver problems and overall health.
Maltese: Id-doża għandha mnejn tkun teħtieġ li tiġi mnaqqsa skont il-problemi tal-kliewi, problemi tal-fwied u saħħa globali.
English: Metoclopramide can be used in combination with oral analgesics to improve the absorption of analgesics in acute migraine.
Maltese: Metoclopramide jista' jintuża f'kombinazzjoni ma' analġeżiċi orali sabiex jitjieb l-assorbiment ta' analġeżiċi f'emigranja akuta.
English: Hepatic impairment: In patients with severe hepatic impairment, the dose should be reduced by 50% (see section 5.2).
Maltese: Indeboliment tal-fwied F'pazjenti b'indeboliment sever tal-fwied, id-doża għandha titnaqqas b'50% (ara sezzjoni 5.2).
English: In patients with renal impairment or with severe hepatic impairment, a dose reduction is recommended (see section 4.2).
Maltese: F'pazjenti b'indeboliment ral-kliewi jew b'indeboliment tal-fwied sever, tnaqqis fid-doża hu rakkomandat (ara sezzjoni 4.2).
English: 30 mg strength prolonged release preparations
Maltese: Id-doża rakkomandata hi ta' 30 mg darba kuljum
English: Your doctor may perform blood tests to check your blood pigment levels.
Maltese: - Storja medika riċenti ta' proktite jew emorraġija fir-rektum.
English: Metoclopramide is contraindicated in children aged less than 1 year (see section 4.3).
Maltese: Popolazzjoni pedjatrika Metoclopramide huwa kontraindikat fi tfal li għandhom inqas minn sena (ara sezzjoni 4.3)
English: Paediatric population {Tradename} is indicated in children (aged 1-18 years) for: - Prevention of delayed chemotherapy induced nausea and vomiting (CINV) as a second line option - Treatment of established post operative nausea and vomiting (PONV) as a second line option Oral route
Maltese: - Prevenzjoni ta' tqalligħ u remettar indotti minħabba radjoterapija (RINV) Popolazzjoni pedjatrika {Tradename} hu indikat fi tfal (ta' età bejn 1-18-il sena) għal: - Prevenzjoni ta' tqalligħ u remettar tardiv indotti minħabba kimoterapija (CINV- chemotherapy induced nausea and vomiting) bħala t-tieni linja ppreferuta ta' kura - Trattament ta' tqalligħ u remettar ta' wara l-operazzjoni (PONV - post-operative nausea and vomiting) bħala t-tieni linja ppreferuta ta' kura
English: For rectal formulations
Maltese: Għal formulazzjonijiet fir-rektum
English: Neuroleptic malignant syndrome has been reported with metoclopramide in combination with neuroleptics as well as with metoclopramide monotherapy (see section 4.8).
Maltese: Is-sindromu newrolettiku malinn ġie rapportat b'metoclopramide meta ngħata flimkien ma' newrolettiċi kif ukoll ma' monoterapija b'metoclopramide (ara sezzjoni 4.8). Metoclopramide għandu jitwaqqaf minnufih f'każ ta' sintomi ta' sindromu newrolettiku mallinn u trattament xieraq għandu jinbeda.
English: Do not give {Tradename} to a child less than 1 year of age (see below “Children and adolescents”).
Maltese: M'għandekx tagħti Tradename lil tifel ta' anqas minn sena (ara taħt "Tfal u adolexxenti").
English: Not known Cardiac arrest, occurring shortly after injectable use, and which can be subsequent to bradycardia (see section 4.4); Atrioventricular block,
Maltese: Arrest kardijaku, li jseħħ ftit wara l-użu li jingħata b'injezzjoni, u li jista' jseħħ wara bradikardja (ara sezzjoni 4.4).
English: Children and adolescents For all formulations
Maltese: Tfal u adolexxenti Għal kull formulazzjoni
English: These effects are generally completely reversible after treatment discontinuation, but may require a symptomatic treatment (benzodiazepines in children and/or anticholinergic anti-Parkinsonian medicinal products in adults).
Maltese: Dawn l-effetti ġeneralment huwa kompletament riversibbli wara il-waqfien tat-trattament, imma għandu mnejn ikun meħtieġ trattament sintomatiku (benzodiazepines fi tfal u/jew prodotti mediċinali antikolinerġiċi ta' kontra l-marda tal-Parkinson fl-adulti)
English: For immediate release oral formulations
Maltese: Għal formulazzjoniiet orali ta' rilaxx immedjat
English: Neuroleptics
Maltese: Alluċinazzjoni